Omnicell Inc
NASDAQ:OMCL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Omnicell Inc
No
Economic Moat
Omnicell Inc lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Omnicell Inc
Competitive Advantages
Wide Economic Moat Companies
| Company | Last Price | Price Change | Market Cap | Economic Moat | ||
|---|---|---|---|---|---|---|
|
|
|
NVIDIA Corp
NVDA
|
$177.39 |
+0.8%
|
$4.3T | Wide |
|
|
|
Apple Inc
AAPL
|
$255.92 |
+2.1%
|
$3.8T | Wide |
|
|
|
Alphabet Inc
GOOGL
|
$295.77 |
-0.2%
|
$3.6T | Wide |
|
|
|
Microsoft Corp
MSFT
|
$373.46 |
+1%
|
$2.8T | Wide |
|
|
|
Amazon.com Inc
AMZN
|
$209.77 |
+1.6%
|
$2.3T | Wide |
|
|
|
Taiwan Semiconductor Manufacturing Co Ltd
2330
|
NT$1 810 |
+2.4%
|
$1.5T | Wide |
|
|
|
Meta Platforms Inc
META
|
$574.46 |
+0.1%
|
$1.5T | Wide |
|
|
|
Broadcom Inc
AVGO
|
$314.55 |
-1.8%
|
$1.5T | Wide |
|
|
|
Walmart Inc
WMT
|
$125.79 |
+0.6%
|
$1T | Wide |
|
|
|
Eli Lilly and Co
LLY
|
$935.58 |
-1.3%
|
$884.5B | Wide |
| Company | Last Price | Price Change | Market Cap | Economic Moat | ||
|---|---|---|---|---|---|---|
|
|
|
ABB India Ltd
ABB
|
₹6 142 |
+1.9%
|
$14.3B | Wide |
|
|
|
Cummins India Ltd
CUMMINSIND
|
₹4 646.5 |
+0.2%
|
$14.2B | Wide |
|
|
|
Trent Ltd
TRENT
|
₹3 550.6 |
-0.2%
|
$13.9B | Wide |
|
|
|
Neurocrine Biosciences Inc
NBIX
|
$131.6 |
+2%
|
$13.1B | Wide |
|
|
|
Solar Industries India Ltd
SOLARINDS
|
₹13 109 |
+0.7%
|
$13.1B | Wide |
|
|
|
BSE Ltd
BSE
|
₹2 851.4 |
+0.9%
|
$12.8B | Wide |
|
|
|
GE Vernova T&D India Ltd
GVT&D
|
₹3 822.2 |
+1.8%
|
$10.8B | Wide |
|
|
|
National Aluminium Co Ltd
NATIONALUM
|
₹401.8 |
+5%
|
$8.1B | Wide |
|
|
|
Multi Commodity Exchange of India Ltd
MCX
|
₹2 443 |
+2.1%
|
$6.9B | Wide |
|
|
|
Central Depository Services (India) Ltd
CDSL
|
₹1 186.3 |
+0.1%
|
$2.7B | Wide |
Omnicell Inc
Glance View
Omnicell Inc. stands at the intersection of healthcare and technology, sculpting the landscape of medication management systems with its innovative spirit. Founded in 1992, Omnicell has evolved from a small enterprise into a leading provider of automated solutions for medication and supply dispensing, inventory management, and analytics. The company’s core offering, its automated dispensing systems, reshapes how hospitals, pharmacies, and healthcare providers manage medications. By utilizing cutting-edge technology, Omnicell improves efficiency, reduces medication errors, and cuts down on healthcare costs. These systems are embedded in the workflow of healthcare facilities, ensuring that medication management becomes seamless, thus elevating patient safety and clinical outcomes. Revenue streams flow robustly from both product sales and associated services. Omnicell garners income by selling its advanced hardware systems, which include everything from pharmacy carousels to medication robotic systems, and supplements these sales with software solutions that offer predictive analytics and inventory optimization. Beyond the initial sale, a significant part of their business model includes recurring revenue through service contracts, software updates, and customer support. This dual approach not only ensures a steady cash flow but also strengthens customer relationships by consistently providing value over time. As the healthcare industry increasingly leans on technology for streamlined operations and cost management, Omnicell’s strategic positioning allows it to capitalize on the demand for sophisticated medication management solutions.
Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.
The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.
Note: This research does not account for survivorship bias. Past performance is not indicative of future results.
Economic Moat